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Abstract

Photodynamic therapy is a modern treatment with applications in several medical
specialties, which has been intensely studied in the last years. The main indications in
dermatology are actinic keratosis, superficial basal cell carcinoma and Bowen's diseasecommon skin disorders in which photodynamic therapy proved its efficacy. At present, the
use of photodynamic therapy for the treatment of other skin disorders is profoundly
researched. Pain is the most common and redoubtable adverse effect of photodynamic
therapy and it is the most important factor affecting the patient's adherence to treatment. The
aim of this article is to look over the most recent medical studies regarding pain in PDT,
with emphasis on the factors affecting the occurrence of pain and the most recent strategies
for controlling photodynamic therapy- related pain.
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Introduction

porphyrins

Photodynamic therapy (PDT) is a modern
treatment which has been used in several medical
specialties in the last years, especially for the
treatment of various cancers and infections, but
also

inflammatory

disorders

and

photo-

rejuvenation. It involves the selective uptake of a
photosensitizing agent by the targeted cell or
tissue, light activation and cell destruction in the
presence of oxygen (1, 2).

administered

medical student from Munich who was studying
the effect of acridine orange on the cultures of
Paramecium caudatum. The student noticed that
the cultures were destroyed when they were
exposed to both acridine and light but not when
they were exposed to acridine alone. Based on this
discovery, his professor dr. Von Tappeiner, further
researched the phenomenon and later called it

non-porphyrins

systemically

or

and

are

topically.

A

photosensitizer must be selectively taken by the
targeted tissue, absorb light of an appropriate
wavelength and destroy specific cells or tissues.
The most commonly used photosensitizers in
dermatology are 5-aminolevulinic acid (ALA) and
its ester, methyl aminolevulinate (MAL) (3, 6).
Several light sources can be used in PDT,
including

PDT was first described by Oscar Raab, a

and

non-coherent

light

sources,

light-

emitting diodes and lasers. Natural light has also
been used with some good results. The wavelength
is also important. Tissue penetration is best
between 600 and 1200 nm. However, oxygen
cannot be generated by wavelengths longer than
800 nm. Porphyrins, the most commonly used
sensitizers, maximally absorb light of 400-410 nm
- the Soret band, but also have minor absorption
peaks at 630 nm (2, 3, 7).

photodynamic action. The therapy was extensively Discussion
studied in the last hundred years in an attempt to
discover better sensitizers, light sources or
techniques. The discovery of photosensitizers like
hematoporphyrin

(Meyer

Betz,

1913),

hematoporphyrin derivative (Schwartz, 1955) and
5-aminolevulinic acid (Kennedy and Pottier, 1990)
are key moments in the history of PDT (3-5).

• Mechanism of action
The topically or systemically administered
photosensitizer is activated by light of an adequate
wavelength. The sensitizer absorbs the light and is
transformed from its ground state into the excited
singlet state, which is very unstable. Therefore, the
drug can either emit fluorescence and go back to

PDT requires the concomitant presence of a the ground state, or it can undergo electron spin
photosensitizer, light with an adequate wavelength conversion to its triplet state which is more stable.
and oxygen (2). Most photosensitizers have a In the presence of oxygen, this molecule either
tetrapyrrole structure. They can be classified as reacts with a substrate and forms radicals (type I
20
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reactions) or the energy is transferred to oxygen still scarce. However, studies show promising
and forms reactive oxygen species (type II results (11-15). Contraindications to PDT are
reaction).

As a result, the lipids, proteins and porphyria, systemic lupus erythematosus, non-

nucleic acids of targeted cells are altered and responsive tumors, allergy to the photosensitizing
apoptosis occurs. The blood vessels are also agent and photosensitive dermatoses (13).
affected and ischemia contributes to the death of

Adverse reactions

cells (8-10).
• Applications of photodynamic therapy in
dermatology. PDT has several applications in
dermatology,

including

neoplastic

diseases,

inflammatory

diseases,

microbial

diseases,

photoaging and rejuvenation (Table 1). While there
is clear evidence on the effectiveness of PDT for
actinic keratosis, BCC, especially the superficial
type and Bowen's disease, the data regarding the
use of PDT for other dermatological disorders is

Acute adverse reactions are photosensitivity,
pain and inflammation. Photosensitivity depends
on the administration route. Therefore, it is greater
after systemic administration and it is localized
after topical administration. Pain is the most
common

and

redoubtable

adverse

effect.

Inflammation manifesting as edema, induration,
purpura and blistering can occur and can
sometimes be serious, leading to tissue necrosis (1,
11). Chronic adverse reactions are rare and include

Strength of
Type of lesion
recommendation
Neoplastic diseases

Inflammatory diseases



actinic keratoses

A



acne vulgaris



squamous cell carcinoma

D



rosacea



basal cell carcinoma

B



hidradenitis suppurativa

N/A, case reports



Bowen's disease

A



morphea

N/A, case reports



cutaneous T cell lymphoma

C



psoriasis

D



extramammary Paget's disease

C

photorejuvenation

viral warts

B



condyloma acuminata

B



cutaneous leishmaniasis

B



onychomycosis

N/A

Cosmetic dermatology

Infectious diseases


B

B



N/A, case reports

Table 1. Applications of PDT in dermatology
A - good evidence; B - fair evidence; C - poor evidence; D - fair evidence to support the rejection of the procedure; N/A
not available
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scarring, post inflammatory hypopigmentation and mean value of VAS of 4.6. 21% of patients
hyperpigmentation (1, 11).


experienced severe pain (VAS 7-10) while 31%
had little or no pain (VAS 0-3) (16).

Pain in photodynamic therapy
Pain is the most common side-effect

The mechanism of pain in PDT is still

associated with PDT and it is the most important unknown. Aδ and C fibers are the major painfactor that affects the patient's adherence to conducting nerve fiber systems. In PDT, pain is
treatment.

Most

patients

undergoing

PDT mainly mediated through the unmyelinated afferent

experience some degree of pain, which can be C-fibers. C-fibers innervate polymodal receptors
mild, manifesting as stinging or burning, or more which respond to thermal, mechanical and
severe. It usually occurs during exposure, being chemical pain. The P substance and other
most intense after a few minutes of irradiation, and neurotransmitters are also involved in PDT related
decreases towards the end of the session. Few pain. Hyperthermia, reactive oxygen species and
patients however also experience post-procedural inflammation have been discussed as possible
pain. Therefore, some patients interrupt treatment triggers for pain in PDT. Nerve stimulation by
sessions while others do not return for further ALA through Aδ and C fibers might also play a
treatments (11, 16, 17).
Most studies assessing pain during PDT
use the visual analogue scale (VAS) for pain. The
VAS for pain is a measurement instrument which

role (16).


Factors contributing to pain in PDT for
dermatological disorders
Lesion type: actinic keratosis seem to be

tries to measure the amount of pain felt by the
patient across a continuum ranging from none
(marked as 0) to unbearable pain (marked as 10)
(Figure 1). The assessment of pain is subjective,
the results depending on psychosocial factors and
personal characteristics of the patient. According

more painful than BCC and Bowen's disease. The
treatment of acne lesions with PDT is also painful.
A study performed by Schleyer et. al on 12
patients with psoriasis treated with ALA-PDT
showed unsatisfactory results, irradiation being

to some studies 20% of patients rate pain over six interrupted several times due to pain and severe
burning sensation. PDT for viral warts is also
on the VAS (18, 19, 20).
A study performed by Sandberg et. al in painful (11, 19, 21, 22).
2006 investigated pain related to ALA-PDT in 91

Location: lesion located in well innervated

patients treated for actinic keratosis. VAS was areas such as the head, hands and perineum are
used for pain assessment. The authors found a more painful.
22
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Extent of lesions: larger lesions or more systems, namely GABA-transporters. Therefore
extensive treated areas are associated with more ALA might be transported into nerve endings by
pain than small lesions (16, 17).

GABA receptors. GABA is the primary inhibitory

Type of photosensitizer: MAL and ALA are neurotransmitter in the central nervous system and
the most widely used photosensitizing agents in abnormal

levels

can

determine

neurological

dermatology. Studies show that ALA-PDT is conditions and pain. The uptake of MAL on the
associated with more pain than MAL-PDT. A other hand is cell dependent, MAL being
study performed by Gaal et. al in 2011, which transported by non-polar amino-acid transporters
included 87 patients with 182 lesions (AK, BCC (19, 24, 26, 27).
and Bowen's disease) found that 21 of the 24

Total dose of light and light intensity. Total

treatments associated with intolerable pain that dose of light, measured in joules/cm2 must be
required treatment discontinuation were done with differentiated from the intensity of light, measured
ALA-PDT (23). Wiegell et. al compared pain in watts/cm2. Higher total dose of light and higher
related to ALA-PDT with pain related to MAL- light intensity both seem to be associated with
PDT in 20 volunteers with tape-stripped normal higher levels of pain. Zeitouni et. al performed a
skin. Patients were randomized to receive either retrospective review of pain control by a two-step
ALA-PDT or MAL-PDT. The authors found that irradiance schedule during ALA-PDT, in an
ALA-PDT was associated with more pain than existing dermatology data base. Their study
MAL-PDT (24). Kasche et. al. performed a study included 14 patients who had initially received an
on 69 patients with AK who received either ALA- irradiance of 30 or 50 mW/cm2 for 20 J/cm2
PDT or MAL-PDT. The authors found that followed by 150 mW/cm2 for 200-300 J/cm2. The
treatment had to be interrupted in 54% of patients author obtained a median VAS score of 1 and
receiving ALA-PDT and 14% of patients receiving conlcuded that the two step irradiance protocole is
MAL-PDT (25).

effective in minimising pain (28). The same group

One explanation might be that MAL is of researchers later performed a study on 21
more lipophilic than ALA and penetrates tissues patients with 25 superficial BCCs who were
better. It also determines better accumulation of treated with MAL-PDT. Patients were randomized
protoporphyrin IX in abnormal cells (19, 22). to receive either laser with irradiance at 40 or 50
Another explanation could be that ALA and γ- mW/cm2 or LED with irradiance at 35 mW/cm2.
aminobutyric acid (GABA) have similar structures After that all patients received irradiance at 70
and are carried into cells by the same carrier mW/cm2 for a total of 75 J/cm2. Pain was

Pain in photodynamic therapy

measured using the VAS. The authors report that side of the face and PDL-PDT on the other side.
pain was minimal in the LED cohort (35/70 Pain was significantly lower in the PDL-PDT
mW/cm2), was mild in the 40/70 mW/cm2 laser group. 78.7% of patients treated with PDL-PDT
cohort and was higher in the 50/70 mW/cm2 laser and 32.8 of patients in the LED group declared that
cohort (29). Radakovic et. al. performed a study on they would undergo the treatment again (33).
27 patients with at least 3 AKs on the face or scalp Some studies showed that daylight PDT is
who were treated with ALA and irradiated with 70, associated with less pain than conventional PDT.
100 or 140 j/cm2. The authors report no Wiegell et. al showed in a study performed on 29
statistically significant difference between the patients with AK, published in 2008, that LEDthree light doses regarding the degree of PDT- PDT and daylight PDT have similar efficacy,
induced pain (30).

LED-PDT being more painful than daylight-PDT

Wavelength. Morton et. al compared ALA- (34). Braathen also conducted a study on 18
PDT with red light and green light in the treatment patients with AKs who were treated with daylight of Bowen's disease. The study included 61 PDT. Only one patients reported pain, scored as 5
patients. The authors concluded that PDT with on the VAS (35).
green light is less effective than PDT with red light

Number of sessions. The second session of

in the treatment of Bowen's disease. However, the PD is more painful than the first one.
severity of the experienced pain was similar

Skin phototype. Phototypes

and 2 are

between the two cohorts, with red light being more associated with more pain (19).
painful than green light (22, 31).



Source of light. Several sources of light

Pain management
Since pain is the most important side effect

have been tried in order to increase efficacy and of PDT, several strategies for controlling pain have
decrease pain. Babilas et. al performed a study on been researched. Until now no ideal method for
25 patients with AKs who received MAL-PDT pain management was found, probably because the
and irradiation with LED on one side of the face precise mechanism of pain was not discovered
and variable pulsed light (VPL) on the other side (19).
of the face. The authors showed that pain was

Topical anesthetics

significantly lower on the side treated with VPL

Topical anesthetics have failed to prove

(32). Kessels et. al compared PDT with LED with their efficacy in controlling the pain associated
PDT with pulsed dye laser (PDL) in 61 patients with PDT. EMLA, an eutectic mixture of lidocaine
with AK, the patients receiving LED-PDL on one 2,5% and prilocaine 2.5%, is the most widely used
24
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topical anesthetic. Langan et al performed a of pain determined by PDT (38). Topical lidocaine
randomized, double blind study on 14 patients with cream associated with pretreatment with urea 40%
AK treated with two sessions of ALA, who to enhance lidocaine penetration also failed to
received EMLA on one session and placebo prove its efficacy in reducing PDT -related pain
(Aqueous cream) on the other session. The authors (39).
report no difference between EMLA and placebo

Locally injected anesthetics

(36).

Locally injected anesthetics and nerve
Tetracaine gel was also evaluated as a block showed better results in reducing pain than

potential local anesthetic in PDT. Holmes et. al topical anesthetics. Therefore, locally injected
performed a prospective, double blind, placebo lidocaine, mepivacaine, ropovacaine, prilocaine
controlled study on 42 patients with non- and epinephrine all showed some good results in
melanoma skin cancer who were randomized to the management of PDT-related pain. Paoli et. al
receive either tetracaine gel or placebo gel. The performed a study on 16 patients with AKs and
pain in the tetracaine group was slightly lower than
pain in the placebo group (VAS 4.0 vs. VAS 4.5).
However, the difference was not statistically
significant between the two groups (37).
Sandberg et. al tested the efficacy of

used nerve block with mepivacaine and adrenaline
on one side of the face and then performed PDT on
both sides of the face. The authors report that the
pain was significantly reduced on the anaesthetized
side compared to the non-anesthetized side (40).

capsaicin cream as a pain-reducing agent in 6
patients with AKs who applied he cream 3-5 times
a day for a week before treatment. The authors
obtained no significant pain relief. However, all
patients presented local adverse reactions (16).
Morphine gel also showed no efficacy in

Borelli et. al assessed the effect of subcutaneous
infiltration anesthesia (SIA) on pain in PDT in 16
patients who received SIA on one side of the face
and oral analgesics only for the other side of the
face and concluded that SIA decreases pain in PDT

controlling PDT-related pain in a double-blind, significantly more than oral analgesia (41).
Conscious sedation
placebo controlled study performed on 28 patients
(27 AKs and 1 BCC) who were randomized to

Conscious sedation with inhaled 50%

receive either morphine 0.3% gel or placebo nitrous oxide/ oxygen has been recently reported in
cream. The authors reported identical maximum association with PDT and according to the authors,
pain scores (5.5) and concluded that opioid it could be an alternative for classical anesthetics
receptors might not be involved in the mechanism (42, 43).
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